Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2013Journal of ObesityOpen Access

Vagal Blocking Improves Glycemic Control and Elevated Blood Pressure in Obese Subjects with Type 2 Diabetes Mellitus

View Full Paper
Ask AI
Bookmark
Share

Key result

Intermittent vagal blocking in obese subjects with type 2 diabetes resulted in 25% excess weight loss and a 1.0% reduction in HbA1c at 12 months (P<0.0001 and P=0.02, respectively).

Why the study?

Does intermittent vagal blocking improve weight loss, glycemic control, and blood pressure in obese subjects with type 2 diabetes mellitus?

Population

28 obese subjects with type 2 diabetes mellitus, mean age 51 ± 2 years, BMI 37 ± 1 kg/m2, 17 females/9 males.

Design

Cohort, open-label

Follow-up

12 months

Authors

SSScott A. ShikoraJTJ. ToouliMHMiguel F. Herrera

Discussion

Loading...

Member takes

Overview

Should not yet change practice in obese T2DM; leaves open efficacy and safety in randomized trials.

Structured PICO

Does intermittent vagal blocking improve weight loss, glycemic control, and blood pressure in obese subjects with type 2 diabetes mellitus?

P
Population
28 obese adults with type 2 diabetes mellitus implanted with a vagal blocking device and followed for 12 months.
I
Intervention
Intermittent vagal blocking (VBLOC) using an implanted device (Maestro Rechargeable System) for up to 12 months.
O
Outcome
Weight loss, HbA1c, fasting blood glucose, and blood pressure evaluated at 1 week to 12 months.surrogate

Main Result

p-value: p=<0.0001

Intermittent vagal blocking in obese patients with type 2 diabetes is associated with significant weight loss, improved HbA1c, and reduced blood pressure at 12 months.

Cite This Study

Shikora et al. (2013) studied Obesity with Type 2 Diabetes Mellitus (n=28). Intermittent vagal blocking (VBLOC) was evaluated on excess weight loss percentage (% EWL) at 12 months (p=<0.0001). Intermittent vagal blocking in obese subjects with type 2 diabetes resulted in 25% excess weight loss and a 1.0% reduction in HbA1c at 12 months (P<0.0001 and P=0.02, respectively).

synapsesocial.com/papers/6a7784d5df493903fd1eff5ehttps://doi.org/10.1155/2013/245683
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Vagal Nerve Function in Obesity: Therapeutic Implications2009 · 57 citations
  2. 2Effect of Laparoscopic Roux-En Y Gastric Bypass on Type 2 Diabetes Mellitus2003 · 1,189 citations
  3. 3Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study.1983 · 4,273 citations
  4. 4The Disease Burden Associated With Overweight and Obesity1999 · 4,829 citations
  5. 5Benefits of moderate weight loss in patients with type 2 diabetes2009 · 57 citations